Supplement-related liver injuries rose from 7% to 20% between 2004-2013.
The number of liver injuries related to herbal and dietary supplements is up, according to new data from the Drug-Induced Liver Injury Network (DILIN) published in the latest issue of Hepatology. While the number of liver injuries related to supplements is lower than the number attributed to medication, herbal supplements were responsible for a significantly higher proportion of severe cases of liver injury compared to medications, DILIN reports.
DILIN reports that 709 liver injury cases (85%) recorded at eight U.S. referral centers in 2004–2013 were due to medication. There were also 130 cases (15.5%) caused by herbal and dietary supplements-marking an increase from 7% to 20%. Specifically, 85 cases (65% of the supplement total) were caused by non-bodybuilding supplements, and 45 cases (35% of the supplement total) were caused by bodybuilding supplements. The study enrolled 839 patients.
Hepatotoxicity cases were “evaluated by expert opinion.” Criteria included cases of jaundice or coagulopathy (clotting) and elevations in alanine or asparate aminotransferase or alkaline phosphatase levels. Liver injuries included liver-related death or liver transplantation.
Notably, DILIN reports that there was a “significantly higher proportion of severe cases” within the supplements group, compared to the conventional medication group.
“Contrary to widespread belief, this study demonstrates that [herbal and dietary supplement] products are not always safe,” the authors write. “Indeed, our data suggest that, relative to conventional medication-induced hepatotoxicity, liver injury from [herbal and dietary supplements not only occurs, but also may be increasing in frequency over time in the populations surrounding the DILIN centers and, probably, in the United States as a whole.”
The researchers did note that overall supplement usage in the United States has concurrently gone up, according to NHANES data. Also, they warn that one challenge in assessing potential hepatotoxicity related to supplements is that many supplement products contain multiple ingredients, which may make it difficult to analyze toxic potential. Potential interactions between medication and supplements may further fuzz the picture. Finally, adulterated and contaminated supplements may be responsible for damages, as well.
Given these factors, the Council for Responsible Nutrition (CRN; Washington, DC) says that while this study is well-designed and that its revelations should be cause for supplement manufacturers to continue adhering to strict adverse-event reporting (AER) protocols, as required by law, the report “does not warrant any blanket warnings in the area of supplements or supplement regulations, except to remind consumers to talk with their doctor about the supplements they take.”
CRN points out that “dietary supplement regulation includes a serious adverse event reporting system that would help identify patterns were they to exist.”
“Questions also remain about whether the serious results were idiosyncratic, related to adulterated products (which are illegal), associated with taking the product off-label, or some other confounding factor," CRN states. The association further urges FDA to remove spiked supplements from the marketplace.
Established in 2003, DILIN is supported by the National Institute of Diabetes and Digestive and Kidney Diseases and was founded to identify and characterize cases of liver injuries associated with medications and supplements.
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine jennifer.grebow@ubm.com
Photo © iStockphoto.com/spanteldotru
Balchem’s Newest Launch Optifolin+® Brings Innovation to the Folate Market
November 15th 2024Supplement launches featuring 5-MTHF are on the rise with double digit growth. In this episode of Nutritional Outlook’s podcast, we explore Optifolin+®, a new ingredient in the market that offers essential nutrition from prenatal through adulthood. Join us as we uncover the potential impact of the next evolution in folate, setting the stage for a healthier future.
The Nutritional Outlook Podcast Episode 35: Prioritizing Women's Health Research and Innovation
October 28th 2024On this month's episode of the Nutritional Outlook Podcast, Cepham's founder and president, Anand Swaroop, discusses the company's recent announcement to prioritize women's health research and innovation.
Balchem’s Newest Launch Optifolin+® Brings Innovation to the Folate Market
November 15th 2024Supplement launches featuring 5-MTHF are on the rise with double digit growth. In this episode of Nutritional Outlook’s podcast, we explore Optifolin+®, a new ingredient in the market that offers essential nutrition from prenatal through adulthood. Join us as we uncover the potential impact of the next evolution in folate, setting the stage for a healthier future.
The Nutritional Outlook Podcast Episode 35: Prioritizing Women's Health Research and Innovation
October 28th 2024On this month's episode of the Nutritional Outlook Podcast, Cepham's founder and president, Anand Swaroop, discusses the company's recent announcement to prioritize women's health research and innovation.
2 Commerce Drive
Cranbury, NJ 08512